Equities Research Analysts’ Upgrades for October, 9th (CLDX, DNKN, IRDM, PHX, PI, PLT, PQG, PRMW, PRTK, PTE)

Equities Research Analysts’ upgrades for Wednesday, October 9th:

Celldex Therapeutics (NASDAQ:CLDX) was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. Zacks Investment Research currently has $2.25 target price on the stock. According to Zacks, “Following the discontinuation of glembatumumab vedotin studies in 2018, Celldex is focused on developing its cancer pipeline candidates including CDX-301 and CDX-1140. They are being developed for lymphoma as well as the lucrative lung cancer market. Celldex’s collaboration with Bristol-Myers is encouraging as it lends solid support as well as expertise. Meanwhile, the Kolltan acquisition added some interesting candidates to the company’s pipeline. However, the failure of glembatumumab vedotin was a major setback and further pipeline setbacks will severely impact Celldex. The company depends entirely on licensing agreements, contracts and grants for revenues. Shares have underperformed the industry in the past year.”

Dunkin Brands Group (NASDAQ:DNKN) was upgraded by analysts at OTR Global from a mixed rating to a positive rating.

Iridium Communications (NASDAQ:IRDM) was upgraded by analysts at Sidoti from a neutral rating to a buy rating. The firm currently has $26.00 price target on the stock.

Panhandle Oil and Gas (NYSE:PHX) was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. They currently have $16.00 target price on the stock. According to Zacks, “Panhandle Royalty Company is engaged in the ownership, acquisition and management of mineral properties and the exploration for and development of oil and gas properties, principally involving wells located on the Company’s mineral interests. Panhandle and its wholly owned subsidiary, Wood Oil Company, mineral properties and other oil and gas interests are located primarily in Oklahoma New Mexico, Texas, and twenty other states. “

IMPINJ (NASDAQ:PI) was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. The firm currently has $35.00 target price on the stock. According to Zacks, “Impinj, Inc. is a provider of referral and information network radio frequency identification solutions to the retail, pharmaceutical, healthcare, food and beverage and other industries. The company’s products include Indy Reader Chips which consists of integrated radio chips and supporting SDKs; Monza Tag Chips, which deliver memory options and extended features to RFID tags and Speedway fixed RFID readers and antennas for RFID-based information. Impinj, Inc. is based in Seattle, Washington. “

Plantronics (NYSE:PLT) was upgraded by analysts at Zacks Investment Research from a sell rating to a hold rating. According to Zacks, “Plantronics is a global leader in audio communications for businesses and consumers. They have pioneered new trends in audio technology for 50 years, creating innovative products that allow people to simply communicate. From unified communication solutions to Bluetooth® headsets, they deliver uncompromising quality, an ideal experience, and extraordinary service. Plantronics is used by every company in the Fortune 100, as well as 911 dispatch, air traffic control and the New York Stock Exchange. “

PQ Group (NYSE:PQG) was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. Zacks Investment Research currently has $17.00 target price on the stock. According to Zacks, “PQ Group Holdings Inc. is an integrated, provider of catalysts, specialty materials and chemicals and services. It operates primarily in North America, Europe, South America and Asia. The company serves refinery, emissions control and petrochemical industries. PQ Group Holdings Inc. is based in MALVERN, United States. “

Primo Water (NASDAQ:PRMW) was upgraded by analysts at Zacks Investment Research from a sell rating to a hold rating. According to Zacks, “Prime Water Corporation operates as a provider of three- and five-gallon purified bottled water and water dispensers sold through major retailers nationwide. The Company’s water bottles can be sanitized and reused, crushed and recycled. Also, it provides water bottle exchange solution for its retail customers. It operates through two segments, Primo Bottled Water Exchange and Primo Products. Prime Water Corporation is headquartered in Winston-Salem, North Carolina. “

Paratek Pharmaceuticals (NASDAQ:PRTK) was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. The firm currently has $4.50 target price on the stock. According to Zacks, “Paratek Pharmaceuticals, Inc. is a biopharmaceutical company. The Company focuses on the discovery, development, and commercialization of therapeutics that treat infectious disease agents. The Company’s lead product candidate, omadacycline, is a tetracycline-derived antibiotic being developed for use as a first-line monotherapy for serious community-acquired bacterial infections where antibiotic resistance is of concern for treating physicians. Its second product candidate, WC 3035 is a tetracycline-derived compound designed for use in the treatment of acne and rosacea. Paratek Pharmaceuticals, Inc., formerly known as Transcept Pharmaceuticals, Inc., is based in United States. “

Polarityte (NASDAQ:PTE) was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. The firm currently has $4.00 price target on the stock. According to Zacks, “PolarityTE, Inc. creates regenerative medicine and provides tissue engineering platform. It develops and obtains regulatory approval for technology which utilizes a patient’s own tissue substrates for regeneration of skin, bone, muscle, cartilage and nerves. The product pipeline comprises SkinTE, OsteoTE, AngioTE, MyoTE, CarteTE, AdiposeTE and NeuralTE. PolarityTE, Inc., formerly known as Majesco Entertainment Company, is headquatered in Salt lake City, Utah. “

Protagonist Therapeutics (NASDAQ:PTGX) was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. They currently have $13.00 target price on the stock. According to Zacks, “Protagonist Therapeutics, Inc. is a clinical-stage biopharmaceutical company with a proprietary technology platform focused on discovering and developing peptide-based new chemical entities to address significant unmet medical needs. The Company’s initial lead product candidates consists of PTG-100 and PTG-200, which have the potential to transform the existing treatment paradigm for inflammatory bowel disease, a GI disease consisting primarily of ulcerative colitis and Crohn’s disease; PTG-300, an injectable hepcidin mimetic. Protagonist Therapeutics, Inc. is based in Milpitas, United States. “

Proteostasis Therapeutics (NASDAQ:PTI) was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. They currently have $1.00 target price on the stock. According to Zacks, “Proteostasis Therapeutics, Inc. is a biopharmaceutical company which focuses on the discovery and development of novel therapeutics to treat diseases caused by an imbalance in the proteostasis network primarily in the United States. Proteostasis Therapeutics, Inc. is based in Cambridge, Massachusetts. “

Portola Pharmaceuticals (NASDAQ:PTLA) was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. They currently have $30.00 target price on the stock. According to Zacks, “Portola Pharmaceuticals, Inc. is a biopharmaceutical company .It focuses on the development and commercialization of therapeutics for thrombosis, other hematologic disorders and inflammation. Portola Pharmaceuticals, Inc. is headquartered in South San Francisco, California. “

Quanterix (NASDAQ:QTRX) was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. Zacks Investment Research currently has $24.00 price target on the stock. According to Zacks, “Quanterix Corporation is a developer of tools in high definition diagnostics. The Company focuses on research and diagnostics for brain injuries, heart disease, cancer and other diseases with its technology. It offers Simoa consumables, which include Simoa Discs, Simoa Cuvettes, Simoa Sealing Oil, Simoa Buffers and Disposable Tips. The company services include Simoa Accelerator Lab and custom assay development services. Quanterix Corporation is based in LEXINGTON, United States. “

QuickLogic (NASDAQ:QUIK) was upgraded by analysts at Zacks Investment Research from a sell rating to a hold rating. According to Zacks, “QuickLogic Corporation is a semiconductor provider of ultra-low power, comprehensive, flexible sensor processing solutions enabling significantly longer battery life for the Smartphone, Wearable, and IoT markets. They are the only company integrating multi-core processing, programmable logic, sensor fusion and context aware algorithms, and embedded software. QuickLogic accelerates the pace of innovation for always-on motion, light, environmental, location, and voice-enabled user experiences. “

Receive News & Ratings for Celldex Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celldex Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.